Literature DB >> 17675486

TCR affinity promotes CD8+ T cell expansion by regulating survival.

Mirja Hommel1, Philip D Hodgkin.   

Abstract

Ligation with high affinity ligands are known to induce T lymphocytes to become fully activated effector cells while ligation with low affinity ligands (or partial agonists) may result in a delayed or incomplete response. We have examined the quantitative features of CD8(+) T cell proliferation induced by peptides of different TCR affinities at a range of concentrations in the mouse OT-I model. Both the frequency of cells responding and the average time taken for cells to reach their first division are affected by peptide concentration and affinity. Consecutive division times, however, remained largely unaffected by these variables. Importantly, we identified affinity to be the sole regulator of cell death in subsequent division. These results suggest a mechanism whereby TCR affinity detection can modulate the subsequent rate of T cell growth and ensure the dominance of higher affinity clones over time.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17675486     DOI: 10.4049/jimmunol.179.4.2250

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Determining the expected variability of immune responses using the cyton model.

Authors:  Vijay G Subramanian; Ken R Duffy; Marian L Turner; Philip D Hodgkin
Journal:  J Math Biol       Date:  2007-11-03       Impact factor: 2.259

2.  Reproducible selection of high avidity CD8+ T-cell clones following secondary acute virus infection.

Authors:  Tania Cukalac; Jesseka Chadderton; Andreas Handel; Peter C Doherty; Stephen J Turner; Paul G Thomas; Nicole L La Gruta
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-13       Impact factor: 11.205

3.  A Myc-dependent division timer complements a cell-death timer to regulate T cell and B cell responses.

Authors:  Susanne Heinzel; Tran Binh Giang; Andrey Kan; Julia M Marchingo; Bryan K Lye; Lynn M Corcoran; Philip D Hodgkin
Journal:  Nat Immunol       Date:  2016-11-07       Impact factor: 25.606

4.  Priming with very low-affinity peptide ligands gives rise to CD8(+) T-cell effectors with enhanced function but with greater susceptibility to transforming growth factor (TGF)β-mediated suppression.

Authors:  Jeremy A O'Sullivan; Andrew Zloza; Frederick J Kohlhapp; Tamson V Moore; Andrew T Lacek; Nickolai O Dulin; José A Guevara-Patiño
Journal:  Cancer Immunol Immunother       Date:  2011-06-17       Impact factor: 6.968

5.  T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice.

Authors:  Florian Wiede; Benjamin J Shields; Sock Hui Chew; Konstantinos Kyparissoudis; Catherine van Vliet; Sandra Galic; Michel L Tremblay; Sarah M Russell; Dale I Godfrey; Tony Tiganis
Journal:  J Clin Invest       Date:  2011-11-14       Impact factor: 14.808

6.  Stimulation of naive CD8+ T cells by a variant viral epitope induces activation and enhanced apoptosis.

Authors:  Rebecca M Ream; Jie Sun; Thomas J Braciale
Journal:  J Immunol       Date:  2010-02-05       Impact factor: 5.422

7.  Interferon regulatory factor 4 sustains CD8(+) T cell expansion and effector differentiation.

Authors:  Shuyu Yao; Bruno Fernando Buzo; Duy Pham; Li Jiang; Elizabeth J Taparowsky; Mark H Kaplan; Jie Sun
Journal:  Immunity       Date:  2013-11-07       Impact factor: 31.745

8.  Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model.

Authors:  John R Ohlfest; Brian M Andersen; Adam J Litterman; Junzhe Xia; Christopher A Pennell; Lauryn E Swier; Andres M Salazar; Michael R Olin
Journal:  J Immunol       Date:  2012-12-17       Impact factor: 5.422

9.  Quantifying T lymphocyte turnover.

Authors:  Rob J De Boer; Alan S Perelson
Journal:  J Theor Biol       Date:  2013-01-09       Impact factor: 2.691

10.  T Cell Priming by Activated Nlrc5-Deficient Dendritic Cells Is Unaffected despite Partially Reduced MHC Class I Levels.

Authors:  Giorgia Rota; Kristina Ludigs; Stefanie Siegert; Aubry Tardivel; Leonor Morgado; Walter Reith; Aude De Gassart; Greta Guarda
Journal:  J Immunol       Date:  2016-03-04       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.